
    
      This is a Phase II study that will be open label and include a total of five patients who
      will receive the investigational product. These patients will have histological testing to
      rule out competing etiologies and require 3rd party adjudication/confirmation on agreement of
      the diagnosis. These patients will undergo 12 weeks of ixekizumab dosed every 2 weeks with
      follow-up until week 16.
    
  